The scope of the action includes the development and validation of a sustainable governance model for the evaluation of type/brand-specific seasonal influenza vaccine effectiveness in Europe, through collaboration between public and private partners. Furthermore, the scope of the action is to build an EU/EEA-wide recognised and accepted platform for influenza vaccine effectiveness studies, including the development of tools for communication and dissemination of the results obtained from the studies.Expected Impact:It is expected that the action will result in better information for healthcare professionals and the general public about the performance of the influenza vaccines in use, better information on the performance of national immunization programmes, improved understanding of the benefits of influenza vaccination, and better understanding of the factors that impact influenza vaccine effectiveness. The action will likely positively influence societal acceptance of influenza vaccines, result in improved vaccine coverage in the EU and ultimately reduced disease burden.If successful, the model could be expanded to evaluation of all other vaccines used in national/sub-national immunisation programmes.